Clinical Trials Browser

Leukemia, Myeloid × Idarubicin × 30 days × Clear all

NCT07604233 2026-06-01

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

Phase 1/2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid